Phosphorylation of huntingtin at Ser421 in YAC128 neurons is associated with protection of YAC128 neurons from NMDA-mediated excitotoxicity and is modulated by PP1 and PP2A

Journal of Neuroscience

Volumn 30, Issue 43, 2010, Pages 14318-14329

  Metzler, Martina ^a   Gan, Lu ^a   Mazarei, Gelareh ^a   Graham, Rona K ^a   Liu, Lili ^a   Bissada, Nagat ^a   Lu, Ge ^a   Leavitt, Blair R ^a   Hayden, Michael R ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 6; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DOPAMINE; HUNTINGTIN; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PHOSPHOPROTEIN DARPP 32; PHOSPHOPROTEIN PHOSPHATASE 1; PHOSPHOPROTEIN PHOSPHATASE 2A; SERINE DERIVATIVE; AMINO ACID RECEPTOR BLOCKING AGENT; AMINO ACID RECEPTOR STIMULATING AGENT; DIZOCILPINE MALEATE; DOPAMINE 1 RECEPTOR; HD PROTEIN, HUMAN; N METHYLASPARTIC ACID; NERVE PROTEIN; NUCLEAR PROTEIN; PHOSPHOPROTEIN PHOSPHATASE 2; PPP1R1B PROTEIN, HUMAN; PPP2CA PROTEIN, HUMAN; QUINOLINIC ACID;

ANIMAL CELL; ARTICLE; BRAIN NERVE CELL; CELL DEATH; CLINICAL FEATURE; CONTROLLED STUDY; CORPUS STRIATUM; EMBRYO; ENZYME ACTIVITY; EXCITOTOXICITY; HUNTINGTON CHOREA; MOUSE; NEUROMODULATION; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TRANSGENE; ANIMAL; BIOSYNTHESIS; CELL CULTURE; CEREBELLUM; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; GENETICS; MALE; METABOLISM; MUTATION; NERVE CELL; PHOSPHORYLATION; PHYSIOLOGY; STEREOTACTIC PROCEDURE;

ANIMALS; CELL DEATH; CELLS, CULTURED; CEREBELLUM; CORPUS STRIATUM; DIZOCILPINE MALEATE; DOPAMINE AND CAMP-REGULATED PHOSPHOPROTEIN 32; EXCITATORY AMINO ACID AGONISTS; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; MALE; MICE; MUTATION; N-METHYLASPARTATE; NERVE TISSUE PROTEINS; NEURONS; NUCLEAR PROTEINS; PHOSPHORYLATION; PROTEIN PHOSPHATASE 1; PROTEIN PHOSPHATASE 2; QUINOLINIC ACID; RECEPTORS, DOPAMINE D1; RECEPTORS, N-METHYL-D-ASPARTATE; STEREOTAXIC TECHNIQUES;

EID: 78049342155     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.1589-10.2010     Document Type: Article

References (53)

1. 2+ -dependent dephosphorylation of DARPP-32 by protein phosphatase 2A. Proc Natl Acad Sci U S A 104:9876-9881.
2. Beal MF, Kowall NW, Ellison DW, Mazurek MF, Swartz KJ, Martin JB (1986) Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 321:168-171.
3. Bibb JA, Yan Z, Svenningsson P, Snyder GL, Pieribone VA, Horiuchi A, Nairn AC, Messer A, Greengard P (2000) Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice. Proc Natl Acad Sci U S A 97:6809-6814. (Pubitemid 30412796)
4. 2+ - and stimulus duration-dependent switch for hippocampal gene expression. Cell 87:1203-1214.
5. Colin E, Zala D, Liot G, Rangone H, Borrell-Pagès M, Li XJ, Saudou F, Humbert S (2008) Huntingtin phosphorylation acts as a molecular switch for anterograde/retrograde transport in neurons. EMBO J 27:2124-2134.
6. Das S, Grunert M, Williams L, Vincent SR (1997) NMDA and D1 receptors regulate the phosphorylation of CREB and the induction of c-fos in striatal neurons in primary culture. Synapse 25:227-233. (Pubitemid 27123023)
7. Ehrnhoefer DE, Butland SL, Pouladi MA, Hayden MR (2009) Mouse models of Huntington disease: variations on a theme. Dis Model Mech 2:123-129.
8. Fan MM, Raymond LA (2007) N-Methyl-D-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease. Prog Neurobiol 81:272-293.
9. Garcia A, Cayla X, Guergnon J, Dessauge F, Hospital V, Rebollo MP, Fleischer A, Rebollo A (2003) Serine/threonine protein phosphatases PP1 and PP2A are key players in apoptosis. Biochimie 85:721-726. (Pubitemid 37383789)
10. Gauthier LR, Charrin BC, Borrell-Pagès M, Dompierre JP, Rangone H, Cordelières FP, De Mey J, MacDonald ME, Lessmann V, Humbert S, Saudou F (2004) Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 118:127-138. (Pubitemid 38902819)
11. Gee CE, Mansuy IM (2005) Protein phosphatases and their potential implications in neuroprotective processes. Cell Mol Life Sci 62:1120-1130.
12. Graham RK, Deng Y, Slow EJ, Haigh B, Bissada N, Lu G, Pearson J, Shehadeh J, Bertram L, Murphy Z, Warby SC, Doty CN, Roy S, Wellington CL, Leavitt BR, Raymond LA, Nicholson DW, Hayden MR (2006) Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell 125:1179-1191. (Pubitemid 43866195)
13. Graham RK, Pouladi MA, Joshi P, Lu G, Deng Y, Wu NP, Figueroa BE, Metzler M, André VM, Slow EJ, Raymond L, Friedlander R, Levine MS, Leavitt BR, Hayden MR (2009) Differential susceptibility to excitotoxic stress in YAC128 mouse models of Huntington disease between initiation and progression of disease. J Neurosci 29:2193-2204.
14. Gu X, Greiner ER, Mishra R, Kodali R, Osmand A, Finkbeiner S, Steffan JS, Thompson LM, Wetzel R, Yang XW (2009) Serines 13 and 16 are critical determinants of full-length human mutant huntingtin induced disease pathogenesis in HD mice. Neuron 64:828-840.
15. Gupta V, Ogawa AK, Du X, Houk KN, Armstrong RW (1997) A model for binding of structurally diverse natural product inhibitors of protein phosphatases PP1 and PP2A. J Med Chem 40:3199-3206. (Pubitemid 27413744)
16. Halpain S, Girault JA, Greengard P (1990) Activation of NMDA receptors induces dephosphorylation of DARPP-32 in rat striatal slices. Nature 343:369-372.
17. Hardingham GE, Fukunaga Y, Bading H (2002) Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat Neurosci 5:405-414. (Pubitemid 34454245)
18. Harper PS (1999) Huntington's disease: a clinical, genetic and molecular model for polyglutamine repeat disorders. Philos Trans R Soc Lond B Biol Sci 354:957-961.
19. Hermel E, Gafni J, Propp SS, Leavitt BR, Wellington CL, Young JE, Hackam AS, Logvinova AV, Peel AL, Chen SF, Hook V, Singaraja R, Krajewski S, Goldsmith PC, Ellerby HM, Hayden MR, Bredesen DE, Ellerby LM (2004) Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease. Cell Death Differ 11:424-438. (Pubitemid 38489420)
20. Hodges A, Strand AD, Aragaki AK, Kuhn A, Sengstag T, Hughes G, Elliston LA, Hartog C, Goldstein DR, Thu D, Hollingsworth ZR, Collin F, Synek B, Holmans PA, Young AB, Wexler NS, Delorenzi M, Kooperberg C, Augood SJ, Faull RL, et al. (2006) Regional and cellular gene expression changes in human Huntington's disease brain. Hum Mol Genet 15: 965-977. (Pubitemid 43338237)
21. Humbert S, Bryson EA, Cordelières FP, Connors NC, Datta SR, Finkbeiner S, Greenberg ME, Saudou F (2002) The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. Dev Cell 2:831-837. (Pubitemid 34650078)
22. Hurlbert MS, Zhou W, Wasmeier C, Kaddis FG, Hutton JC, Freed CR (1999) Mice transgenic for an expanded CAG repeat in the Huntington's disease gene develop diabetes. Diabetes 48:649-651. (Pubitemid 29106885)
23. Josefsen K, Nielsen MD, Jørgensen KH, Bock T, Nø rremølle A, Sørensen SA, Naver B, Hasholt L (2008) Impaired glucose tolerance in the R6/1 transgenic mouse model of Huntington's disease. J Neuroendocrinol 20: 165-172. (Pubitemid 351147003)
24. Leavitt BR, van Raamsdonk JM, Shehadeh J, Fernandes H, Murphy Z, Graham RK, Wellington CL, Raymond LA, Hayden MR (2006) Wildtype huntingtin protects neurons from excitotoxicity. J Neurochem 96:1121-1129.
25. Lerch JP, Carroll JB, Spring S, Bertram LN, Schwab C, Hayden MR, Henkelman RM (2008) Automated deformation analysis in the YAC128 Huntington disease mouse model. Neuroimage 39:32-39. (Pubitemid 350102212)
26. Luthi-Carter R, Strand A, Peters NL, Solano SM, Hollingsworth ZR, Menon AS, Frey AS, Spektor BS, Penney EB, Schilling G, Ross CA, Borchelt DR, Tapscott SJ, Young AB, Cha JH, Olson JM (2000) Decreased expression of striatal signaling genes in a mouse model of Huntington's disease.Hum Mol Genet 9:1259-1271.
27. Mansuy IM, Shenolikar S (2006) Protein serine/threonine phosphatases in neuronal plasticity and disorders of learning and memory. Trends Neurosci 29:679-686. (Pubitemid 44794536)
28. Metzler M, Gan L, Wong TP, Liu L, Helm J, Liu L, Georgiou J, Wang Y, Bissada N, Cheng K, Roder JC, Wang YT, Hayden MR (2007) NMDA receptor function and NMDA receptor-dependent phosphorylation of huntingtin is altered by the endocytic protein HIP1. J Neurosci 27: 2298-2308. (Pubitemid 46340973)
29. Milnerwood AJ, Gladding CM, Pouladi MA, Kaufman AM, Hines RM, Boyd JD, Ko RW, Vasuta OC, Graham RK, Hayden MR, Murphy TH, Raymond LA (2010) Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington's disease mice. Neuron 65:178-190.
30. Nishi A, Snyder GL, Greengard P (1997) Bidirectional regulation of DARPP-32 phosphorylation by dopamine. J Neurosci 17:8147-8155. (Pubitemid 27461039)
31. Pardo R, Colin E, Régulier E, Aebischer P, Déglon N, Humbert S, Saudou F (2006) Inhibition of calcineurin by FK506 protects against polyglutamine-huntingtin toxicity through an increase of huntingtin phosphorylation at S421. J Neurosci 26:1635-1645. (Pubitemid 43237034)
32. Perkinton MS, Ip JK, Wood GL, Crossthwaite AJ, Williams RJ (2002) Phosphatidylinositol 3-kinase is a central mediator of NMDA receptor signalling to MAP kinase (Erk1/2), Akt/PKB and CREB in striatal neurones. J Neurochem 80:239-254.
33. Pineda JR, Pardo R, Zala D, Yu H, Humbert S, Saudou F (2009) Genetic and pharmacological inhibition of calcineurin corrects the BDNF transport defect in Huntington's disease. Mol Brain 2:33.
34. Platholi J, Heerdt PM, Lim Tung HY, Hemmings HC Jr (2008) Activation of brain protein phosphatase-1(I) following cardiac arrest and resuscitation involving an interaction with 14-3-3 gamma. J Neurochem 105:2029-2038. (Pubitemid 351678513)
35. Rigamonti D, Sipione S, Goffredo D, Zuccato C, Fossale E, Cattaneo E (2001) Huntingtin's neuroprotective activity occurs via inhibition of procaspase-9 processing. J Biol Chem 276:14545-14548.
36. Sala C, Rudolph-Correia S, Sheng M (2000) Developmentally regulated NMDA receptor-dependent dephosphorylation of cAMP response element-binding protein (CREB) in hippocampal neurons. J Neurosci 20:3529-3536. (Pubitemid 30266214)
37. Shehadeh J, Fernandes HB, Zeron Mullins MM, Graham RK, Leavitt BR, Hayden MR, Raymond LA (2006) Striatal neuronal apoptosis is preferentially enhanced by NMDA receptor activation in YAC transgenic mouse model of Huntington disease. Neurobiol Dis 21:392-403. (Pubitemid 43099862)
38. Sheppeck JE 2nd, Gauss CM, Chamberlin AR (1997) Inhibition of the Ser-Thr phosphatases PP1 and PP2A by naturally occurring toxins. Bioorg Med Chem 5:1739-1750.
39. Slow EJ, van Raamsdonk J, Rogers D, Coleman SH, Graham RK, Deng Y, Oh R, Bissada N, Hossain SM, Yang YZ, Li XJ, Simpson EM, Gutekunst CA, Leavitt BR, Hayden MR (2003) Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet 12:1555-1567. (Pubitemid 36857303)
40. r 32 kDa)/protein phosphatase-1 pathway regulates dephosphorylation of the NMDA receptor. J Neurosci 18:10297-10303.
41. Sutton G, Chandler LJ (2002) Activity-dependent NMDA receptor-mediated activation of protein kinase B/Akt in cortical neuronal cultures. J Neurochem 82:1097-1105. (Pubitemid 34966622)
42. Svenningsson P, Lindskog M, Rognoni F, Fredholm BB, Greengard P, Fisone G (1998) Activation of adenosine A2A and dopamine D1 receptors stimulates cyclic AMP-dependent phosphorylation of DARPP-32 in distinct populations of striatal projection neurons. Neuroscience 84: 223-228. (Pubitemid 28081539)
43. Svenningsson P, Nishi A, Fisone G, Girault JA, Nairn AC, Greengard P (2004) DARPP-32: an integrator of neurotransmission. Annu Rev Pharmacol Toxicol 44:269-296.
44. Szatmari E, Habas A, Yang P, Zheng JJ, Hagg T, Hetman M (2005) A positive feedback loop between glycogen synthase kinase 3beta and protein phosphatase 1 after stimulation of NR2B NMDA receptors in forebrain neurons. J Biol Chem 280:37526-37535. (Pubitemid 41642361)
45. Van Hoof C, Goris J (2003) Phosphatases in apoptosis: to be or not to be, PP2A is in the heart of the question. Biochim Biophys Acta 1640:97-104.
46. Van Raamsdonk JM, Metzler M, Slow E, Pearson J, Schwab C, Carroll J, Graham RK, Leavitt BR, Hayden MR (2007) Phenotypic abnormalities in the YAC128 mouse model of Huntington disease are penetrant on multiple genetic backgrounds and modulated by strain. Neurobiol Dis 26:189-200. (Pubitemid 46436497)
47. Warby SC, Chan EY, Metzler M, Gan L, Singaraja RR, Crocker SF, Robertson HA, Hayden MR (2005) Huntingtin phosphorylation on serine 421 is significantly reduced in the striatum and by polyglutamine expansion in vivo. Hum Mol Genet 14:1569-1577. (Pubitemid 40823464)
48. Warby SC, Doty CN, Graham RK, Shively J, Singaraja RR, Hayden MR (2009) Phosphorylation of huntingtin reduces the accumulation of its nuclear fragments. Mol Cell Neurosci 40:121-127.
49. Xifró X, García-Martínez JM, Del Toro D, Alberch J, Pérez-Navarro E (2008) Calcineurin is involved in the early activation of NMDA-mediated cell death in mutant huntingtin knock-in striatal cells. J Neurochem 105:1596-1612.
50. Xifró X, Giralt A, Saavedra A, García-Martínez JM, Díaz-Hernández M, Lucas JJ, Alberch J, Pérez-Navarro E (2009) Reduced calcineurin protein levels and activity in exon-1 mouse models of Huntington's disease: role in excitotoxicity. Neurobiol Dis 36:461-469.
51. Zeron MM, Hansson O, Chen N, Wellington CL, Leavitt BR, Brundin P, Hayden MR, Raymond LA (2002) Increased sensitivity to N-methyl-Daspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron 33:849-860.
52. Zhang SJ, Steijaert MN, Lau D, Schütz G, Delucinge-Vivier C, Descombes P, Bading H (2007) Decoding NMDA receptor signaling: identification of genomic programs specifying neuronal survival and death. Neuron 53:549-562. (Pubitemid 46216756)
53. Zhang Y, Leavitt BR, van Raamsdonk JM, Dragatsis I, Goldowitz D, MacDonald ME, Hayden MR, Friedlander RM (2006) Huntingtin inhibits caspase-3 activation. EMBO J 25:5896-5906.